Novartis AG's histone deacetylase (HDAC) inhibitor Farydak (panobinostat; also known as Faridak) has secured approval in Europe for the treatment of multiple myeloma – making it the first drug of this class to reach the European market.
Farydak is approved for use in combination with bortezomib (Millennium Pharmaceuticals' Velcade) and dexamethasone, for the treatment of adult patients...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
